Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Femasys Inc. stock logo
FEMY
Femasys
$1.37
+4.6%		$2.13
$1.26
▼
$22.20
$11.47M-2.13109,308 shs72,720 shs
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$0.93
+3.8%		$4.64
$0.82
▼
$29.34
$12.33M2.91.18 million shs85,571 shs
IRIDEX Corporation stock logo
IRIX
IRIDEX
$0.66
-3.3%		$0.71
$0.61
▼
$1.65
$11.55M0.6464,918 shs21,726 shs
Nuwellis, Inc. stock logo
NUWE
Nuwellis
$4.58
-1.7%		$6.22
$2.52
▼
$1,556.07
$2.48M0.032.11 million shs31,309 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Femasys Inc. stock logo
FEMY
Femasys
0.00%0.00%-33.17%-48.50%-91.80%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
0.00%-4.78%-78.02%-88.92%-93.14%
IRIDEX Corporation stock logo
IRIX
IRIDEX
0.00%-7.66%-26.79%-20.84%-37.09%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
0.00%-19.37%-24.62%-65.85%-99.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Femasys Inc. stock logo
FEMY
Femasys
$1.37
+4.6%		$2.13
$1.26
▼
$22.20
$11.47M-2.13109,308 shs72,720 shs
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$0.93
+3.8%		$4.64
$0.82
▼
$29.34
$12.33M2.91.18 million shs85,571 shs
IRIDEX Corporation stock logo
IRIX
IRIDEX
$0.66
-3.3%		$0.71
$0.61
▼
$1.65
$11.55M0.6464,918 shs21,726 shs
Nuwellis, Inc. stock logo
NUWE
Nuwellis
$4.58
-1.7%		$6.22
$2.52
▼
$1,556.07
$2.48M0.032.11 million shs31,309 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Femasys Inc. stock logo
FEMY
Femasys
0.00%0.00%-33.17%-48.50%-91.80%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
0.00%-4.78%-78.02%-88.92%-93.14%
IRIDEX Corporation stock logo
IRIX
IRIDEX
0.00%-7.66%-26.79%-20.84%-37.09%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
0.00%-19.37%-24.62%-65.85%-99.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Femasys Inc. stock logo
FEMY
Femasys
2.50
Moderate Buy$50.003,549.64% Upside
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
2.40
Hold$50.255,304.39% Upside
IRIDEX Corporation stock logo
IRIX
IRIDEX
2.00
Hold$3.00356.34% Upside
Nuwellis, Inc. stock logo
NUWE
Nuwellis
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NUWE, IRIX, GUTS, and FEMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/3/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/20/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/19/2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$5.00
10/19/2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetEqual Weight$4.00
10/2/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/21/2026
Nuwellis, Inc. stock logo
NUWE
Nuwellis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/18/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/4/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/3/2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/20/2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Femasys Inc. stock logo
FEMY
Femasys
$2.29M5.01N/AN/A$2.01 per share0.68
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$90K136.99N/AN/A$0.83 per share1.12
IRIDEX Corporation stock logo
IRIX
IRIDEX
$52.67M0.22N/AN/A($0.06) per share-10.96
Nuwellis, Inc. stock logo
NUWE
Nuwellis
$9.01M0.27N/AN/A$497.85 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Femasys Inc. stock logo
FEMY
Femasys
-$18.63M-$3.53N/AN/AN/A-534.36%-225.97%-74.68%11/17/2026 (Estimated)
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$140.95M-$10.56N/AN/AN/AN/A-1,362.10%-84.89%11/12/2026 (Estimated)
IRIDEX Corporation stock logo
IRIX
IRIDEX
-$4.44M-$0.20N/AN/AN/A-6.88%N/A-12.55%11/17/2026 (Estimated)
Nuwellis, Inc. stock logo
NUWE
Nuwellis
-$17.52M-$1,193.38N/AN/AN/A-123.38%-623.14%-147.34%11/12/2026 (Estimated)

Latest NUWE, IRIX, GUTS, and FEMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2026Q3 2026
Femasys Inc. stock logo
FEMY
Femasys
-$0.6050N/AN/AN/A$0.62 millionN/A
11/17/2026Q3 2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
-$0.04N/AN/AN/A$12.65 millionN/A
11/12/2026Q3 2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$1.59N/AN/AN/AN/AN/A
11/12/2026Q3 2026
Nuwellis, Inc. stock logo
NUWE
Nuwellis
-$122.85N/AN/AN/A$2.51 millionN/A
8/18/2026Q2 2026
IRIDEX Corporation stock logo
IRIX
IRIDEX
-$0.01-$0.07-$0.06-$0.07$13.59 million$12.57 million
8/14/2026Q2 2026
Femasys Inc. stock logo
FEMY
Femasys
-$1.31-$1.33-$0.02-$1.33$0.73 million$0.33 million
8/13/2026Q2 2026
Nuwellis, Inc. stock logo
NUWE
Nuwellis
-$214.20-$239.76-$25.56-$26.64$2.42 million$1.97 million
8/10/2026Q2 2026
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$1.62-$1.44+$0.18-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/AN/AN/AN/AN/A
IRIDEX Corporation stock logo
IRIX
IRIDEX
N/AN/AN/AN/AN/A
Nuwellis, Inc. stock logo
NUWE
Nuwellis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Femasys Inc. stock logo
FEMY
Femasys
0.89
2.14
0.55
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
1.41
3.15
3.15
IRIDEX Corporation stock logo
IRIX
IRIDEX
N/A
1.82
1.08
Nuwellis, Inc. stock logo
NUWE
Nuwellis
N/A
1.97
1.54

Institutional Ownership

CompanyInstitutional Ownership
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
IRIDEX Corporation stock logo
IRIX
IRIDEX
20.10%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
3.13%

Insider Ownership

CompanyInsider Ownership
Femasys Inc. stock logo
FEMY
Femasys
7.75%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
8.36%
IRIDEX Corporation stock logo
IRIX
IRIDEX
8.60%
Nuwellis, Inc. stock logo
NUWE
Nuwellis
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Femasys Inc. stock logo
FEMY
Femasys
548.38 million7.73 millionNot Optionable
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
7313.26 million12.15 millionN/A
IRIDEX Corporation stock logo
IRIX
IRIDEX
10817.57 million16.05 millionOptionable
Nuwellis, Inc. stock logo
NUWE
Nuwellis
38541,000532,000Not Optionable

Recent News About These Companies

Nuwellis Submits FDA Application To Expand Aquadex Use In Pediatric Patients
November 5 at 2:56 PM  |  rttnews.comhttps://www.rttnews.com/3710662/nuwellis-submits-fda-application-to-expand-aquadex-use-in-pediatric-patients.aspx
Nuwellis Seeks FDA Clearance to Expand Aquadex Use in Pediatric Patients
November 5 at 2:56 PM  |  marketscreener.comM
Nuwellis Hatches Strategic Commercial Agreement With Atrility Medical
November 5 at 2:56 PM  |  mpo-mag.comM
Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
November 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396441/26106/en/nuwellis-submits-fda-510-k-to-expand-aquadex-smartflow-indication-to-include-pediatric-patients-weighing-5-kg-and-above.html
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
November 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395310/26106/en/nuwellis-to-report-third-quarter-2026-financial-results-on-november-12.html
Nuwellis To Implement 1-for-9 Reverse Stock Split; Stock Down
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3704524/nuwellis-to-implement-1-for-9-reverse-stock-split-stock-down.aspx
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3388904/26106/en/nuwellis-announces-acceptance-of-multicenter-pediatric-aquadex-study-in-pediatric-nephrology.html
Dale Brady Joins Nuwellis as Principal R&D Engineer
October 26, 2026  |  mpo-mag.comM
Nuwellis, Inc. announces one-for-nine reverse stock split effective October 26, 2026
October 23, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/nuwellis-inc-announces-one-for-nine-reverse-stock-split-effective-october-26-2026/ar-AA2fVWLR
Nuwellis Unveils Next-Generation Aquadex Platform Strategy
October 20, 2026  |  mpo-mag.comM
Nuwellis, Inc. (NASDAQ:NUWE) Shares Shorted: Short Interest Up 339.6% in September
October 13, 2026  |  defenseworld.netD
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377268/26106/en/nuwellis-to-convene-pediatric-medical-nursing-advisory-board-to-advance-development-of-vivian-pediatric-crrt-system.html
Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372906/26106/en/nuwellis-to-highlight-advancements-in-fluid-management-across-pediatric-care-critical-care-and-heart-failure-at-leading-october-medical-conferences.html
Nuwellis Appoints Brian Johnson As Director Of Quality And Regulatory Affairs
September 17, 2026  |  rttnews.comhttps://www.rttnews.com/3691742/nuwellis-appoints-brian-johnson-as-director-of-quality-and-regulatory-affairs.aspx
Nuwellis reports 31 Aquadex console sales in 2026, expanding recurring revenue opportunity
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/nuwellis-reports-31-aquadex-console-sales-in-2026-expanding-recurring-revenue-opportunity/ar-AA2crmln
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3363979/26106/en/nuwellis-reports-strong-aquadex-console-adoption-with-31-aquadex-smartflow-consoles-sold-year-to-date-meaningfully-expanding-recurring-revenue-opportunity.html
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363154/26106/en/nuwellis-strengthens-organization-with-appointment-of-brian-johnson-as-director-of-quality-and-regulatory-affairs.html
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358658/26106/en/nuwellis-advances-financial-efficiency-strategy-with-improved-gross-margins.html
Nuwellis Highlights Aquadex Growth in Updated Presentation
August 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NUWE/pressreleases/4196920/nuwellis-highlights-aquadex-growth-in-updated-presentation/
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350437/26106/en/nuwellis-expands-critical-care-portfolio-through-strategic-commercial-agreement-with-atrility-medical.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Femasys stock logo

Femasys NASDAQ:FEMY

$1.37 +0.06 (+4.58%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$1.38 +0.00 (+0.36%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Fractyl Health stock logo

Fractyl Health NASDAQ:GUTS

$0.93 +0.03 (+3.80%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$0.94 +0.01 (+0.56%)
As of 11/6/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

IRIDEX stock logo

IRIDEX NASDAQ:IRIX

$0.66 -0.02 (-3.32%)
Closing price 11/6/2026 03:57 PM Eastern
Extended Trading
$0.75 +0.10 (+14.54%)
As of 11/6/2026 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Nuwellis stock logo

Nuwellis NASDAQ:NUWE

$4.58 -0.08 (-1.72%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$4.48 -0.10 (-2.18%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas